OptiBiotix Health PLC Change of accounting year end (0277H)
23 March 2020 - 6:00PM
UK Regulatory
TIDMOPTI
RNS Number : 0277H
OptiBiotix Health PLC
23 March 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Change of accounting year end
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high
choleste r ol, diabetes and skincare, a nn o unces it will be
changing its accounting reference date and financial year end from
30 November to 31 December. The change has been recommended to
align financial reporting with similar companies on other
international exchanges. The change reflects the growing
globalisation of OptiBiotix's products and will facilitate research
analyst coverage with comparator microbiome based companies on
international exchanges like NASDAQ where end of calendar year
financial reporting is more common.
As a result, the Company's next four financial reporting events
will be as follows:
-- Publication of audited accounts for the 13 months to 31
December 2019, by 31 May 2020 (the reporting date remains unchanged
for this year but reported for 13 months not 12)
-- Publication of unaudited interim accounts for the 6 months to
30 June 2020, by 30 September 2020
-- Publication of audited accounts for the 12 months to 31 December 2020, by 30 June 2021
-- Publication of unaudited interim accounts for the 6 months to
30 June 2021, by 30 September 2021
Stephen O'Hara, CEO of OptiBiotix, commented : "Despite the
current general market volatility the board remain focused on
creating a profitable and sustainable global business and building
shareholder value. As we grow the presence of our ingredient
(SlimBiome(R), LPLDL(R)) and product (Cholbiome(R), GoFigure(R),
SlimBiome Medical(R)) brands in global markets we need to
facilitate research analyst coverage with comparator microbiome
based companies on international exchanges. Moving our end of year
forward one month supports this aim. As interest in the microbiome
and OptBiotix's products grows improving international research
coverage of OptiBiotix creates market interest and with it the
opportunity to explore the possibility of a dual listing,
particularly in those markets where there is potential for greater
liquidity and valuation"
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than 20 international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBBGDXLUDDGGG
(END) Dow Jones Newswires
March 23, 2020 03:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024